Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD)

Fábio V. Teixeira

Biosimilars

View PDFchevron_right

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update

Gionata Fiorino

Journal of Crohn's & colitis, 2017

View PDFchevron_right

Marco Daperno

View PDFchevron_right

Tibor Hlavaty

European Journal of Gastroenterology & Hepatology, 2014

View PDFchevron_right

Sender Miszputen

Arquivos de gastroenterologia

View PDFchevron_right

Salvatore Leone

Digestive and Liver Disease, 2020

View PDFchevron_right

Review of the safety with biologics in inflammatory bowel disease

Santiago García-lópez

Journal of IMIDs

View PDFchevron_right

Biologic Therapies for Inflammatory Bowel Diseases

Vassilis Valatas

2013

View PDFchevron_right

Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future

Saurabh dawra

Future pharmacology, 2024

View PDFchevron_right

Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease

Fernando Carballo

Revista Española de Enfermedades Digestivas, 2013

View PDFchevron_right

Maciej Gonciarz

Gastroenterology Review

View PDFchevron_right

Gionata Fiorino

Best practice & research. Clinical gastroenterology, 2014

View PDFchevron_right

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow‐up survey

Sanna Lönnfors

United European Gastroenterology Journal, 2019

View PDFchevron_right

Gionata Fiorino

Expert review of clinical immunology, 2016

View PDFchevron_right

Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group

Serena Arrigo

Pediatric Drugs

View PDFchevron_right

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006

William Sandborn

Gastroenterology, 2007

View PDFchevron_right

Belgian IBD Research Group (BIRD) Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases

Philippe Van Hootegem

Journal of Crohn's and Colitis, 2019

View PDFchevron_right

Maciej Gonciarz

Gastroenterology Review, 2014

View PDFchevron_right

Richard Parrish

Gastroenterology Insights, 2021

View PDFchevron_right

A review article of inflammatory bowel disease treatment and pharmacogenomics

Nashwa Eltantawy

Beni-Suef University Journal of Basic and Applied Sciences, 2023

View PDFchevron_right

P-005: Mechanism of action of potential live biotherapeutics for the treatment of inflammatory bowel disease

George Grant

Journal of Crohn's and Colitis, 2014

View PDFchevron_right

Paolo Lionetti

Journal of Pediatric Gastroenterology and Nutrition, 2015

View PDFchevron_right

The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease

Signe Wildt

Clinical Epidemiology, 2016

View PDFchevron_right

When to use biological agents in inflammatory bowel disease

Rupert Leong

Journal of Gastroenterology and Hepatology, 2012

View PDFchevron_right

Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease

Andrew Macpherson

Pharmaceuticals, 2010

View PDFchevron_right

Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD) (original) (raw)

Related papers